milrinone has been researched along with Disease Models, Animal in 51 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In addition to the positive inotropic effects of milrinone, its immunomodulatory properties that result in decreased cytokine storm can be beneficial during early period of sepsis." | 8.12 | Early administration of milrinone ameliorates lung and kidney injury during sepsis in juvenile rats. ( Bilen, A; Halici, H; Halici, Z; Keskin, H; Kose, D; Mendil, AS; Ozkaraca, M; Tavaci, T; Yuksel, TN, 2022) |
| "After hypercapnia pulmonary hypertension, swine were administered equivalent inhaled milrinone doses of 15 or 50 µg/kg through simple jet nebulization, vibrating mesh nebulization, intratracheal instillation, and intratracheal atomization." | 7.88 | Pharmacokinetics and Pharmacodynamics of Nebulized and Intratracheal Milrinone in a Swine Model of Hypercapnia Pulmonary Hypertension. ( Denault, AY; Gavra, P; Perrault, LP; Théoret, Y; Varin, F, 2018) |
| " We weighed the effects of dobutamine and milrinone as inotropes in mice with cecal ligation and puncture (CLP)-induced polymicrobial sepsis." | 7.85 | Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: attribution to phosphodiesterase 4 upregulation. ( Hattori, K; Hattori, Y; Matsuda, N; Palikhe, S; Sakai, M; Suzuki, T; Tomita, K; Yamashita, S; Yoshimura, N, 2017) |
| "Our study identifies milrinone as a more potent alternative to cilostazol for reversing the repolarization defects responsible for the electrocardiographic and arrhythmic manifestations of Brugada syndrome." | 7.79 | Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome. ( Antzelevitch, C; Koncz, I; Szél, T, 2013) |
| "The authors examined whether milrinone and levosimendan could exert cardiac postconditioning effects in rats under normoglycemia and hyperglycemia, and whether the effects could be mediated by mitochondrial permeability transition pore (mPTP)." | 7.78 | Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts. ( Cho, S; Hara, T; Higashijima, U; Maekawa, T; Matsumoto, S; Sumikawa, K; Tosaka, S, 2012) |
| "Differences between the hypertrophied and normal canine myocardium in response to milrinone are either due to altered levels of cyclic AMP production in left ventricular hypertrophy, to effects of milrinone that are unrelated to cyclic AMP-phosphodiesterase inhibition, or to other differences in hypertrophied hearts." | 7.69 | Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy. ( Cheinberg, BV; Chiu, WC; Kedem, J; Scholz, PM; Tse, J; Weiss, HR, 1994) |
| "To evaluate the effects of milrinone (MIL) on hemodynamics and lung water content, we used 10 mongrel dogs with pulmonary hypertension (PH)." | 7.68 | Effects of milrinone on lung water content in dogs with acute pulmonary hypertension. ( Kobayashi, K; Matsumoto, A; Tajimi, K; Tanaka, H, 1992) |
| "The effects of oral milrinone treatment in cardiomyopathic hamsters with severe congestive heart failure (CHF) were evaluated." | 7.67 | Effects of milrinone treatment in cardiomyopathic hamsters (CHF 147) with severe congestive heart failure. ( Cauchy, MJ; Desjardins, S; Hubert, RS; Mueller, RW, 1989) |
| "Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with early repolarization (ER) pattern." | 5.40 | Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. ( Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B, 2014) |
| "The milrinone plasma level was significantly greater in group III than in the other groups (group I, 0 ng/mL; group II, 1." | 5.40 | Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction. ( Al Kindi, H; Nepotchatykh, O; Paul, A; Prakash, S; Schwertani, A; Shum-Tim, D; You, Z, 2014) |
| "Milrinone was injected intracisternally (0." | 5.36 | Effect of vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries after a subarachnoid hemorrhage in vitro and in vivo: effectiveness of cisternal injection of milrinone. ( Date, I; Hishikawa, T; Iseda, K; Manabe, H; Nishiguchi, M; Ono, S, 2010) |
| "Pretreatment with milrinone markedly enhanced relaxation to prostacyclin and iloprost in PPHN PA, similar to relaxation in control PA." | 5.35 | Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. ( Chen, B; Farrow, KN; Gugino, SF; Kumar, VH; Lakshminrusimha, S; Porta, NF; Russell, JA; Steinhorn, RH, 2009) |
| "Most patients with congestive heart failure (CHF) develop pulmonary venous hypertension, but right ventricular afterload is frequently further elevated by increased pulmonary vascular resistance." | 5.34 | Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. ( Habbazettl, H; Hentschel, T; Koster, A; Kuebler, WM; Kuppe, H; Riad, A; Tschope, C; Weimann, J; Yin, N, 2007) |
| "Pulmonary hypertension was achieved in all animals." | 5.33 | Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. ( Beaver, T; Kirby, DS; Klodell, C; Lobato, EB; Muehlschlegel, J; Sidi, A, 2006) |
| "In addition to the positive inotropic effects of milrinone, its immunomodulatory properties that result in decreased cytokine storm can be beneficial during early period of sepsis." | 4.12 | Early administration of milrinone ameliorates lung and kidney injury during sepsis in juvenile rats. ( Bilen, A; Halici, H; Halici, Z; Keskin, H; Kose, D; Mendil, AS; Ozkaraca, M; Tavaci, T; Yuksel, TN, 2022) |
| "After hypercapnia pulmonary hypertension, swine were administered equivalent inhaled milrinone doses of 15 or 50 µg/kg through simple jet nebulization, vibrating mesh nebulization, intratracheal instillation, and intratracheal atomization." | 3.88 | Pharmacokinetics and Pharmacodynamics of Nebulized and Intratracheal Milrinone in a Swine Model of Hypercapnia Pulmonary Hypertension. ( Denault, AY; Gavra, P; Perrault, LP; Théoret, Y; Varin, F, 2018) |
| " We weighed the effects of dobutamine and milrinone as inotropes in mice with cecal ligation and puncture (CLP)-induced polymicrobial sepsis." | 3.85 | Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: attribution to phosphodiesterase 4 upregulation. ( Hattori, K; Hattori, Y; Matsuda, N; Palikhe, S; Sakai, M; Suzuki, T; Tomita, K; Yamashita, S; Yoshimura, N, 2017) |
| "Our study identifies milrinone as a more potent alternative to cilostazol for reversing the repolarization defects responsible for the electrocardiographic and arrhythmic manifestations of Brugada syndrome." | 3.79 | Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome. ( Antzelevitch, C; Koncz, I; Szél, T, 2013) |
| "The authors examined whether milrinone and levosimendan could exert cardiac postconditioning effects in rats under normoglycemia and hyperglycemia, and whether the effects could be mediated by mitochondrial permeability transition pore (mPTP)." | 3.78 | Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts. ( Cho, S; Hara, T; Higashijima, U; Maekawa, T; Matsumoto, S; Sumikawa, K; Tosaka, S, 2012) |
| " As treatment, three inotropes commonly used for treatment of cardiac failure were infused for 45 mins in separate animal groups-milrinone, dobutamine, and levosimendan." | 3.74 | Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. ( Barraud, D; Damy, T; Faivre, V; Gayat, E; Heymes, C; Mebazaa, A; Payen, D; Shah, AM; Welschbillig, S, 2007) |
| "Differences between the hypertrophied and normal canine myocardium in response to milrinone are either due to altered levels of cyclic AMP production in left ventricular hypertrophy, to effects of milrinone that are unrelated to cyclic AMP-phosphodiesterase inhibition, or to other differences in hypertrophied hearts." | 3.69 | Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy. ( Cheinberg, BV; Chiu, WC; Kedem, J; Scholz, PM; Tse, J; Weiss, HR, 1994) |
| "To evaluate the effects of milrinone (MIL) on hemodynamics and lung water content, we used 10 mongrel dogs with pulmonary hypertension (PH)." | 3.68 | Effects of milrinone on lung water content in dogs with acute pulmonary hypertension. ( Kobayashi, K; Matsumoto, A; Tajimi, K; Tanaka, H, 1992) |
| "The effects of oral milrinone treatment in cardiomyopathic hamsters with severe congestive heart failure (CHF) were evaluated." | 3.67 | Effects of milrinone treatment in cardiomyopathic hamsters (CHF 147) with severe congestive heart failure. ( Cauchy, MJ; Desjardins, S; Hubert, RS; Mueller, RW, 1989) |
| "Traumatic brain injury is still an important health problem worldwide." | 1.91 | Neuroprotective Effects of Milrinone on Acute Traumatic Brain Injury. ( Acıkalın, R; Bilgin, E; Gokten, M; Sezer, A; Sezer, C; Zırh, EB; Zırh, S, 2023) |
| "Milrinone has been shown to be effective in the prevention of tissue damage due to oxidative stress and inflammatory process in the renal of warm ischemia in the experimental NHBDs model and in protecting the renal." | 1.48 | Investigation of the Effect of Milrinone on Renal Damage in an Experimental Non-Heart Beating Donor Model. ( Altınay, S; Batcıoglu, K; Ceylan, MS; Dokur, M; Karadag, M; Kazımoglu, H; Saygılı, Eİ; Uysal, E; Uyumlu, BA, 2018) |
| "Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with early repolarization (ER) pattern." | 1.40 | Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. ( Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B, 2014) |
| "Dobutamine-treated animals had lower perfusion pressures and blood pH compared with epinephrine + milrinone and dopamine + milrinone groups." | 1.40 | Inotropic therapy for right ventricular failure in newborn piglets: effect on contractility, hemodynamics, and interventricular interaction. ( Frederiksen, CA; Heiberg, J; Hyldebrandt, JA; Ravn, HB; Redington, AN; Rothmann, S; Schmidt, MR, 2014) |
| "The milrinone plasma level was significantly greater in group III than in the other groups (group I, 0 ng/mL; group II, 1." | 1.40 | Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction. ( Al Kindi, H; Nepotchatykh, O; Paul, A; Prakash, S; Schwertani, A; Shum-Tim, D; You, Z, 2014) |
| "Sevoflurane/olprinone treatment attenuated the bronchoconstriction induced by the highest dose of Ach with RL being significantly lower (0." | 1.37 | Synergic bronchodilator effects of a phosphodiesterase 3 inhibitor olprinone with a volatile anaesthetic sevoflurane in ovalbumin-sensitised guinea pigs. ( Iwasaki, S; Watanabe, A; Yamakage, M; Zhou, J, 2011) |
| "Milrinone was injected intracisternally (0." | 1.36 | Effect of vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries after a subarachnoid hemorrhage in vitro and in vivo: effectiveness of cisternal injection of milrinone. ( Date, I; Hishikawa, T; Iseda, K; Manabe, H; Nishiguchi, M; Ono, S, 2010) |
| "Pretreatment with milrinone markedly enhanced relaxation to prostacyclin and iloprost in PPHN PA, similar to relaxation in control PA." | 1.35 | Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. ( Chen, B; Farrow, KN; Gugino, SF; Kumar, VH; Lakshminrusimha, S; Porta, NF; Russell, JA; Steinhorn, RH, 2009) |
| "Most patients with congestive heart failure (CHF) develop pulmonary venous hypertension, but right ventricular afterload is frequently further elevated by increased pulmonary vascular resistance." | 1.34 | Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. ( Habbazettl, H; Hentschel, T; Koster, A; Kuebler, WM; Kuppe, H; Riad, A; Tschope, C; Weimann, J; Yin, N, 2007) |
| "Pulmonary hypertension was achieved in all animals." | 1.33 | Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. ( Beaver, T; Kirby, DS; Klodell, C; Lobato, EB; Muehlschlegel, J; Sidi, A, 2006) |
| "Milrinone (M) has been shown to improve left ventricular (LV) performance in animal and human studies." | 1.27 | Evaluation of the vasodilator vs inotropic effect of milrinone using an animal model of left ventricular failure: reversal of disopyramide depression of the myocardium with milrinone. ( Berdoff, R; Goldberg, E; Haimowitz, A; Spivack, G; Tay, S, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.88) | 18.7374 |
| 1990's | 4 (7.84) | 18.2507 |
| 2000's | 15 (29.41) | 29.6817 |
| 2010's | 22 (43.14) | 24.3611 |
| 2020's | 7 (13.73) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Ručilová, V | 1 |
| Świerczek, A | 1 |
| Vanda, D | 1 |
| Funk, P | 1 |
| Lemrová, B | 1 |
| Gawalska, A | 1 |
| Bucki, A | 1 |
| Nowak, B | 1 |
| Zadrożna, M | 1 |
| Pociecha, K | 1 |
| Soural, M | 1 |
| Wyska, E | 1 |
| Pawłowski, M | 1 |
| Chłoń-Rzepa, G | 1 |
| Zajdel, P | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Sezer, C | 3 |
| Zırh, S | 3 |
| Gokten, M | 3 |
| Sezer, A | 3 |
| Acıkalın, R | 3 |
| Bilgin, E | 3 |
| Zırh, EB | 3 |
| Ak, E | 1 |
| Ak, K | 1 |
| Ustandag, UV | 1 |
| Kervancioglu-Demirci, E | 1 |
| Emekli-Alturfan, E | 1 |
| Çetinel, S | 1 |
| Torregroza, C | 1 |
| Maas, K | 1 |
| Feige, K | 1 |
| Raupach, A | 1 |
| Stroethoff, M | 1 |
| Heinen, A | 1 |
| Hollmann, MW | 1 |
| Huhn, R | 1 |
| Seilitz, J | 1 |
| Grafver, I | 1 |
| Kiszakiewicz, L | 1 |
| Oikonomakis, I | 1 |
| Jansson, K | 1 |
| Axelsson, B | 2 |
| Nilsson, KF | 1 |
| Keskin, H | 1 |
| Tavaci, T | 1 |
| Halici, H | 1 |
| Yuksel, TN | 1 |
| Ozkaraca, M | 1 |
| Bilen, A | 1 |
| Kose, D | 1 |
| Mendil, AS | 1 |
| Halici, Z | 1 |
| Sakai, M | 1 |
| Suzuki, T | 1 |
| Tomita, K | 1 |
| Yamashita, S | 1 |
| Palikhe, S | 1 |
| Hattori, K | 1 |
| Yoshimura, N | 1 |
| Matsuda, N | 1 |
| Hattori, Y | 1 |
| Uysal, E | 1 |
| Dokur, M | 1 |
| Altınay, S | 1 |
| Saygılı, Eİ | 1 |
| Batcıoglu, K | 1 |
| Ceylan, MS | 1 |
| Kazımoglu, H | 1 |
| Uyumlu, BA | 1 |
| Karadag, M | 1 |
| Beute, J | 1 |
| Lukkes, M | 1 |
| Koekoek, EP | 1 |
| Nastiti, H | 1 |
| Ganesh, K | 1 |
| de Bruijn, MJ | 1 |
| Hockman, S | 1 |
| van Nimwegen, M | 1 |
| Braunstahl, GJ | 1 |
| Boon, L | 1 |
| Lambrecht, BN | 1 |
| Manganiello, VC | 1 |
| Hendriks, RW | 1 |
| KleinJan, A | 1 |
| Gavra, P | 1 |
| Denault, AY | 1 |
| Théoret, Y | 1 |
| Perrault, LP | 1 |
| Varin, F | 1 |
| Steppan, J | 1 |
| Berkowitz, DE | 1 |
| Nyhan, D | 1 |
| Yagami, K | 1 |
| Yamawaki-Ogata, A | 1 |
| Satake, M | 1 |
| Kaneko, H | 1 |
| Oshima, H | 1 |
| Usui, A | 1 |
| Ueda, Y | 1 |
| Narita, Y | 1 |
| Szél, T | 1 |
| Koncz, I | 3 |
| Antzelevitch, C | 3 |
| Gurabi, Z | 2 |
| Patocskai, B | 2 |
| Nesterenko, VV | 1 |
| Hyldebrandt, JA | 2 |
| Frederiksen, CA | 2 |
| Heiberg, J | 2 |
| Rothmann, S | 1 |
| Redington, AN | 1 |
| Schmidt, MR | 1 |
| Ravn, HB | 2 |
| Al Kindi, H | 1 |
| Paul, A | 1 |
| You, Z | 1 |
| Nepotchatykh, O | 1 |
| Schwertani, A | 1 |
| Prakash, S | 1 |
| Shum-Tim, D | 1 |
| Sivén, E | 1 |
| Agger, P | 1 |
| Wemmelund, KB | 1 |
| Barajas-Martinez, H | 1 |
| Hu, D | 1 |
| Häggmark, S | 1 |
| Svenmarker, S | 1 |
| Johansson, G | 1 |
| Gupta, A | 1 |
| Tydén, H | 1 |
| Wouters, P | 1 |
| Haney, M | 1 |
| Mutoh, T | 2 |
| Nakamura, K | 1 |
| Yamamoto, Y | 1 |
| Tsuru, Y | 1 |
| Tsubone, H | 1 |
| Ishikawa, T | 1 |
| Taki, Y | 1 |
| Lakshminrusimha, S | 2 |
| Porta, NF | 1 |
| Farrow, KN | 1 |
| Chen, B | 1 |
| Gugino, SF | 1 |
| Kumar, VH | 2 |
| Russell, JA | 1 |
| Steinhorn, RH | 1 |
| Zhu, S | 1 |
| White, RE | 1 |
| Barman, SA | 1 |
| Mrabat, H | 1 |
| Beagle, J | 1 |
| Hang, Z | 1 |
| Garg, HG | 1 |
| Hales, CA | 1 |
| Quinn, DA | 1 |
| Nishiguchi, M | 1 |
| Ono, S | 1 |
| Iseda, K | 1 |
| Manabe, H | 1 |
| Hishikawa, T | 1 |
| Date, I | 1 |
| Swartz, DD | 1 |
| Rashid, N | 1 |
| Ma, C | 1 |
| Ryan, RM | 1 |
| Morin, FC | 1 |
| Zhou, J | 1 |
| Iwasaki, S | 1 |
| Watanabe, A | 1 |
| Yamakage, M | 1 |
| Huang, MH | 1 |
| Wu, Y | 1 |
| Nguyen, V | 1 |
| Rastogi, S | 1 |
| McConnell, BK | 1 |
| Wijaya, C | 1 |
| Uretsky, BF | 1 |
| Poh, KK | 1 |
| Tan, HC | 1 |
| Fujise, K | 1 |
| Matsumoto, S | 1 |
| Cho, S | 2 |
| Tosaka, S | 1 |
| Higashijima, U | 1 |
| Maekawa, T | 2 |
| Hara, T | 2 |
| Sumikawa, K | 2 |
| Miura, Y | 1 |
| Matsuda, T | 1 |
| Funakubo, A | 1 |
| Watanabe, S | 1 |
| Kitanishi, R | 1 |
| Saito, M | 1 |
| Hanita, T | 1 |
| Shibata, I | 1 |
| Yoshitomi, O | 1 |
| Ureshino, H | 1 |
| Matot, I | 1 |
| Gozal, Y | 1 |
| Liet, JM | 1 |
| Jacqueline, C | 1 |
| Orsonneau, JL | 1 |
| Gras-Leguen, C | 1 |
| Potel, G | 1 |
| Rozé, JC | 1 |
| Bekhit, AA | 1 |
| Baraka, AM | 1 |
| Lobato, EB | 3 |
| Beaver, T | 1 |
| Muehlschlegel, J | 1 |
| Kirby, DS | 3 |
| Klodell, C | 1 |
| Sidi, A | 3 |
| Stocker, CF | 1 |
| Shekerdemian, LS | 1 |
| Nørgaard, MA | 1 |
| Brizard, CP | 1 |
| Mynard, JP | 1 |
| Horton, SB | 1 |
| Penny, DJ | 1 |
| Palmaers, T | 1 |
| Albrecht, S | 1 |
| Heuser, F | 1 |
| Leuthold, C | 1 |
| Schuettler, J | 1 |
| Schmitz, B | 1 |
| Hentschel, T | 1 |
| Yin, N | 1 |
| Riad, A | 1 |
| Habbazettl, H | 1 |
| Weimann, J | 1 |
| Koster, A | 1 |
| Tschope, C | 1 |
| Kuppe, H | 1 |
| Kuebler, WM | 1 |
| Zhao, H | 1 |
| Quilley, J | 1 |
| Montrose, DC | 1 |
| Rajagopalan, S | 1 |
| Guan, Q | 1 |
| Smith, CJ | 1 |
| Barraud, D | 1 |
| Faivre, V | 1 |
| Damy, T | 1 |
| Welschbillig, S | 1 |
| Gayat, E | 1 |
| Heymes, C | 1 |
| Payen, D | 1 |
| Shah, AM | 1 |
| Mebazaa, A | 1 |
| Muehlschlegel, JD | 2 |
| Muehschlegel, JD | 1 |
| Chiu, WC | 1 |
| Kedem, J | 1 |
| Weiss, HR | 1 |
| Tse, J | 1 |
| Cheinberg, BV | 1 |
| Scholz, PM | 1 |
| Jain, P | 1 |
| Hughes, M | 1 |
| Korlipara, G | 1 |
| Lillis, O | 1 |
| Dervan, JP | 1 |
| Cohn, PF | 1 |
| Qiu, Y | 1 |
| Kraft, P | 1 |
| Lombardi, E | 1 |
| Clancy, J | 1 |
| Tanaka, H | 1 |
| Tajimi, K | 1 |
| Matsumoto, A | 1 |
| Kobayashi, K | 1 |
| Hof, RP | 1 |
| Novosel, D | 1 |
| Evenou, JP | 1 |
| Hof, A | 1 |
| Desjardins, S | 1 |
| Mueller, RW | 1 |
| Hubert, RS | 1 |
| Cauchy, MJ | 1 |
| Goldberg, E | 1 |
| Berdoff, R | 1 |
| Spivack, G | 1 |
| Haimowitz, A | 1 |
| Tay, S | 1 |
| Chong, LJ | 1 |
| Smith, TD | 1 |
| Povzhitkov, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage[NCT02712788] | Phase 2 | 4 participants (Actual) | Interventional | 2016-04-18 | Terminated (stopped due to Completion not feasible due to lack of eligible subjects.) | ||
| Concomitant Milrinone and Esmolol Treatment in Patients With Acute Myocardial Infarction[NCT02098629] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2015-05-31 | Withdrawn (stopped due to Difficulty in enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reported as number for each subject and then will look statistically to see if there is a difference between the active arm and the placebo arm. The Modified Rankin scale is Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to carry out all usual activities, despite some symptoms, 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent, 6 = Death. Higher scores indicate worse outcome. (NCT02712788)
Timeframe: 6 months
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 1.5 |
Reported as number for each subject and then will look statistically to see if there is a difference between the active arm and the placebo arm. THe Modified Rankin Scale is Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to carry out all usual activities, despite some symptoms, 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent, 6 = Death. Higher scores indicate worse outcome. (NCT02712788)
Timeframe: 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 2 |
51 other studies available for milrinone and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Cyclic Nucleotide Phosphodiesterases, Type 7 | 2021 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Neuroprotective Effects of Milrinone on Acute Traumatic Brain Injury.
Topics: Animals; Brain; Brain Injuries; Brain Injuries, Traumatic; Disease Models, Animal; Male; Milrinone; | 2023 |
Neuroprotective Effects of Milrinone on Acute Traumatic Brain Injury.
Topics: Animals; Brain; Brain Injuries; Brain Injuries, Traumatic; Disease Models, Animal; Male; Milrinone; | 2023 |
Neuroprotective Effects of Milrinone on Acute Traumatic Brain Injury.
Topics: Animals; Brain; Brain Injuries; Brain Injuries, Traumatic; Disease Models, Animal; Male; Milrinone; | 2023 |
Neuroprotective Effects of Milrinone on Acute Traumatic Brain Injury.
Topics: Animals; Brain; Brain Injuries; Brain Injuries, Traumatic; Disease Models, Animal; Male; Milrinone; | 2023 |
Neuroprotective Effects of Milrinone on Acute Traumatic Brain Injury.
Topics: Animals; Brain; Brain Injuries; Brain Injuries, Traumatic; Disease Models, Animal; Male; Milrinone; | 2023 |
Neuroprotective Effects of Milrinone on Acute Traumatic Brain Injury.
Topics: Animals; Brain; Brain Injuries; Brain Injuries, Traumatic; Disease Models, Animal; Male; Milrinone; | 2023 |
Neuroprotective Effects of Milrinone on Acute Traumatic Brain Injury.
Topics: Animals; Brain; Brain Injuries; Brain Injuries, Traumatic; Disease Models, Animal; Male; Milrinone; | 2023 |
Neuroprotective Effects of Milrinone on Acute Traumatic Brain Injury.
Topics: Animals; Brain; Brain Injuries; Brain Injuries, Traumatic; Disease Models, Animal; Male; Milrinone; | 2023 |
Neuroprotective Effects of Milrinone on Acute Traumatic Brain Injury.
Topics: Animals; Brain; Brain Injuries; Brain Injuries, Traumatic; Disease Models, Animal; Male; Milrinone; | 2023 |
Milrinone Attenuates Heart and Lung Remote Injury after Abdominal Aortic Cross-Clamping.
Topics: Animals; Antioxidants; Aorta, Abdominal; Caveolin 1; Caveolin 3; Constriction; Disease Models, Anima | 2020 |
Combination of the Phosphodiesterase Inhibitors Sildenafil and Milrinone Induces Cardioprotection With Various Conditioning Strategies.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemody | 2020 |
A Randomized Porcine Study in Low Cardiac Output of Vasoactive and Inotropic Drug Effects on the Gastrointestinal Tract.
Topics: Animals; Cardiac Output, Low; Disease Models, Animal; Female; Gastrointestinal Tract; Male; Milrinon | 2021 |
Early administration of milrinone ameliorates lung and kidney injury during sepsis in juvenile rats.
Topics: Animals; Disease Models, Animal; Kidney; Ligation; Lung; Milrinone; Punctures; Rats; Sepsis | 2022 |
Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: attribution to phosphodiesterase 4 upregulation.
Topics: Adenylyl Cyclases; Animals; Cardiotonic Agents; Cecum; Cyclic AMP; Cyclic Nucleotide Phosphodiestera | 2017 |
Investigation of the Effect of Milrinone on Renal Damage in an Experimental Non-Heart Beating Donor Model.
Topics: Animals; Apoptosis; Disease Models, Animal; Female; Humans; Injections, Intraperitoneal; Kidney; Kid | 2018 |
A pathophysiological role of PDE3 in allergic airway inflammation.
Topics: Allergens; Animals; Asthma; Biopsy; CD11b Antigen; Cells, Cultured; Cyclic Nucleotide Phosphodiester | 2018 |
Pharmacokinetics and Pharmacodynamics of Nebulized and Intratracheal Milrinone in a Swine Model of Hypercapnia Pulmonary Hypertension.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hypercapnia; Hypertension | 2018 |
Ischemic Postconditioning and Milrinone.
Topics: Animals; Disease Models, Animal; Ischemic Postconditioning; Milrinone; Myocardial Reperfusion Injury | 2018 |
Prevention of arterial graft spasm in rats using a vasodilator-eluting biodegradable nano-scaled fibre.
Topics: Absorbable Implants; Animals; Arterial Occlusive Diseases; Calcium Channel Blockers; Constriction, P | 2013 |
Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome.
Topics: Action Potentials; Animals; Brugada Syndrome; Cilostazol; Disease Models, Animal; Dogs; Drug Therapy | 2013 |
Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cilostazol; Disease Models, Animal; Dogs; Electr | 2014 |
Inotropic therapy for right ventricular failure in newborn piglets: effect on contractility, hemodynamics, and interventricular interaction.
Topics: Animals; Animals, Newborn; Blood Pressure; Cardiotonic Agents; Disease Models, Animal; Dobutamine; D | 2014 |
Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Chr | 2014 |
Effects of milrinone and epinephrine or dopamine on biventricular function and hemodynamics in an animal model with right ventricular failure after pulmonary artery banding.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dopamine; Epinephrine; Heart Failure; Heart Ven | 2015 |
Cellular and ionic mechanisms underlying the effects of cilostazol, milrinone, and isoproterenol to suppress arrhythmogenesis in an experimental model of early repolarization syndrome.
Topics: Action Potentials; Animals; Cardiac Electrophysiology; Cardiovascular Agents; Cilostazol; Death, Sud | 2016 |
Effects of Combined Milrinone and Levosimendan Treatment on Systolic and Diastolic Function During Postischemic Myocardial Dysfunction in a Porcine Model.
Topics: Animals; Cardiotonic Agents; Diastole; Disease Models, Animal; Drug Therapy, Combination; Hydrazones | 2016 |
Acute cardiac support with intravenous milrinone promotes recovery from early brain injury in a murine model of severe subarachnoid haemorrhage.
Topics: Administration, Intravenous; Animals; Brain Injuries; Brain Ischemia; Cerebrovascular Circulation; D | 2017 |
Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn.
Topics: Animals; Animals, Newborn; Blotting, Western; Disease Models, Animal; Drug Interactions; Drug Therap | 2009 |
Role of phosphodiesterases in modulation of BKCa channels in hypertensive pulmonary arterial smooth muscle.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Colforsin; Cyclic AMP; Disease Models, Animal; Hypertension, P | 2008 |
Inhibition of HA synthase 3 mRNA expression, with a phosphodiesterase 3 inhibitor, blocks lung injury in a septic ventilated rat model.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Capillary Permea | 2009 |
Effect of vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries after a subarachnoid hemorrhage in vitro and in vivo: effectiveness of cisternal injection of milrinone.
Topics: Angiography; Animals; Basilar Artery; Cyclic AMP; Disease Models, Animal; Dogs; Female; Injections, | 2010 |
Prostacyclin and milrinone by aerosolization improve pulmonary hemodynamics in newborn lambs with experimental pulmonary hypertension.
Topics: Administration, Inhalation; Aerosols; Animals; Animals, Newborn; Antihypertensive Agents; Blood Pres | 2010 |
Synergic bronchodilator effects of a phosphodiesterase 3 inhibitor olprinone with a volatile anaesthetic sevoflurane in ovalbumin-sensitised guinea pigs.
Topics: Acetylcholine; Airway Resistance; Anesthetics, Inhalation; Animals; Bronchial Hyperreactivity; Bronc | 2011 |
Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Apoptosis; Cardiotonic Agents; Cyclic AMP-Dependent | 2011 |
Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts.
Topics: Animals; Blood Glucose; Disease Models, Animal; Hemodynamics; Hydrazones; Hyperglycemia; Male; Milri | 2012 |
Novel modification of an artificial placenta: pumpless arteriovenous extracorporeal life support in a premature lamb model.
Topics: Animals; Arterial Pressure; Artificial Organs; Disease Models, Animal; Dopamine; Equipment Design; E | 2012 |
Milrinone and levosimendan administered after reperfusion improve myocardial stunning in swine.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Drug Administration Schedule; Female; Hemodynam | 2013 |
Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3',5'-Cyclic-AMP Phosphodiestera | 2004 |
The effects of milrinone on hemodynamics in an experimental septic shock model.
Topics: Animals; Dilatation, Pathologic; Disease Models, Animal; Female; Hemodynamics; Hypotension; Milrinon | 2005 |
Novel milrinone analogs of pyridine-3-carbonitrile derivatives as promising cardiotonic agents.
Topics: Adenosine Deaminase; Administration, Oral; Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Diseas | 2005 |
Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3',5'-Cyclic-AMP Phosphodiestera | 2006 |
Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass.
Topics: Age Factors; Animals; Cardiac Output; Cardiac Output, Low; Cardiopulmonary Bypass; Cardiotonic Agent | 2007 |
Milrinone combined with vasopressin improves cardiac index after cardiopulmonary resuscitation in a pig model of myocardial infarction.
Topics: Animals; Blood Pressure; Cardiopulmonary Resuscitation; Coronary Circulation; Disease Models, Animal | 2007 |
Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure.
Topics: Administration, Inhalation; Animals; Cyclic AMP; Cyclic GMP; Disease Models, Animal; Dose-Response R | 2007 |
Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Angioplasty, Balloon; Animals; Aorta; Carboxylic Acids; Cilosta | 2007 |
Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
Topics: Animals; Cardiotonic Agents; Diastole; Disease Models, Animal; Dobutamine; Heart Failure; Hydrazones | 2007 |
Treating metabolic impairment and myocardial stunning with phosphodiesterase inhibitor type III, milrinone, administered prior to coronary artery occlusion in the presence of calcium channel blockade in pigs.
Topics: Analysis of Variance; Animals; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiac Output; | 2007 |
Administration of milrinone before ischemia, in the presence of beta-blockade, to treat metabolic impairment and myocardial stunning in pigs.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Cardiac Output; Cardiotonic Agents; Coronary S | 2008 |
Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aortic Valve Stenosis; Disease Models, Animal; Dogs; H | 1994 |
The effects of chronic oral milrinone therapy on early postinfarction left ventricular remodeling.
Topics: Administration, Oral; Analysis of Variance; Animals; Cardiotonic Agents; Disease Models, Animal; Dru | 1993 |
Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Cyclic AMP; Cycli | 2000 |
Effects of milrinone on lung water content in dogs with acute pulmonary hypertension.
Topics: Acute Disease; Animals; Body Water; Catheterization; Disease Models, Animal; Dogs; Hemodynamics; Hyp | 1992 |
Autonomic nervous system dysfunction alters drug effects: implications for testing drugs for the treatment of heart failure.
Topics: Animals; Autonomic Nervous System; Cardiovascular Agents; Disease Models, Animal; Enalapril; Heart F | 1992 |
Effects of milrinone treatment in cardiomyopathic hamsters (CHF 147) with severe congestive heart failure.
Topics: Animals; Body Weight; Calcium; Cardiomyopathy, Dilated; Cardiotonic Agents; Cricetinae; Disease Mode | 1989 |
Evaluation of the vasodilator vs inotropic effect of milrinone using an animal model of left ventricular failure: reversal of disopyramide depression of the myocardium with milrinone.
Topics: Animals; Cardiac Output; Cardiotonic Agents; Depression, Chemical; Disease Models, Animal; Disopyram | 1987 |
A new model of congestive heart failure in anesthetized dogs.
Topics: Animals; Disease Models, Animal; Dogs; Heart Failure; Hemodynamics; Milrinone; Pyridones | 1985 |